20 Participants Needed

Gingival Grafting Techniques for Gum Recession

HB
SS
Overseen BySarah Startley, DMD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Alabama at Birmingham
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial compares two methods to improve gum tissue quality in patients who lack Keratinized Tissue (KT). One method uses a piece of the patient's own gum tissue, while the other combines a small strip of gum tissue with a special growth-promoting material. The study aims to see which method is better for increasing tissue thickness, improving aesthetics, and minimizing patient discomfort.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is gingival grafting safe for treating gum recession?

Gingival grafting techniques, including the use of acellular dermal matrix (ADM) and autogenous free gingival grafts (FGG), have been studied for safety. These procedures are generally considered safe, but they can cause some discomfort and bleeding at the donor site. ADM is often used to reduce these issues, as it avoids the need to harvest tissue from the patient's own mouth.12345

How does the treatment for gum recession using Free Gingival Graft, Strip Free Gingival Graft + Acellular Dermal Matrix Graft differ from other treatments?

This treatment is unique because it combines a patient's own tissue (autogenous graft) with an acellular dermal matrix (ADM), which is a substitute material that reduces the need for tissue from another part of the patient's mouth, potentially decreasing pain and recovery time. The ADM provides a scaffold for tissue regeneration without the complications associated with harvesting tissue from the patient.12346

What data supports the effectiveness of this treatment for gum recession?

Research shows that using acellular dermal matrix (ADM) grafts can be effective for treating gum recession, similar to traditional methods like connective tissue grafts. ADM grafts are beneficial because they reduce the need for tissue from the patient's own mouth, which can lessen discomfort and complications.13478

Are You a Good Fit for This Trial?

This trial is for patients at the UAB Dental School, over 18 years old, who can understand consent forms and speak English. They should have healthy teeth or implants next to areas lacking keratinized tissue but no active gum disease, previous grafts in those areas, systemic conditions affecting healing, or heavy tobacco use.

Inclusion Criteria

English speaking
My gums do not have enough protective tissue around my teeth or implants.
Able to read and understand informed consent document
See 2 more

Exclusion Criteria

I have had soft tissue grafting at the treatment site.
I have active gum disease.
I am under 18 years old.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo soft tissue grafting using either Free Gingival Graft (FGG) or Strip Gingival Graft with Acellular Dermal Matrix (SGG+ADM)

Immediate procedure
1 visit (in-person)

Follow-up

Participants are monitored for changes in soft tissue quality and quantity, as well as patient-centered outcomes

12 months
Multiple visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Free Gingival Graft
  • Strip Free Gingival Graft (SGG) + Acellular Dermal Matrix Graft (ADM)
Trial Overview The study compares two methods of increasing keratinized tissue around teeth and implants: one using a patient's own gum tissue (Free Gingival Graft) and another combining this with an Acellular Dermal Matrix (Strip Gingival Graft + ADM).
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)Experimental Treatment1 Intervention
Group II: Free gingival graft.Active Control1 Intervention

Free Gingival Graft is already approved in United States, European Union for the following indications:

๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Free Gingival Graft for:
๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as Free Gingival Graft for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials
1,677
Recruited
2,458,000+

Published Research Related to This Trial

A systematic review of 17 controlled trials found that acellular dermal matrix grafts (ADMG) provide similar root coverage and clinical attachment level gains as the gold standard subepithelial connective tissue grafts (SCTG) for treating gingival recession.
ADMG was found to be superior to SCTG in increasing the width of keratinized tissue, making it a suitable alternative for patients who prefer to avoid a second surgical site.
Acellular dermal matrix and subepithelial connective tissue grafts for root coverage: A systematic review.Gallagher, SI., Matthews, DC.[2022]
In a study involving 16 patients with bilateral gingival recessions, the use of Acellular Dermal Matrix (ADM) allograft for root coverage showed similar effectiveness to traditional connective tissue grafts (CTG) in reducing recession and improving clinical attachment after 6 months.
While both techniques were effective, the CTG group experienced a significant increase in the width of keratinized tissue compared to the ADM group, suggesting that while ADM is a viable alternative, it may not provide the same benefits in tissue width.
Comparison of the clinical outcomes of connective tissue and acellular dermal matrix in combination with double papillary flap for root coverage: A 6-month trial.Gholami, GA., Saberi, A., Kadkhodazadeh, M., et al.[2022]
In a clinical trial involving 39 patients with gingival recessions, both acellular dermal matrix allograft (ADMA) and autogenous connective tissue graft (CTG) showed significant improvements in clinical parameters over 5 years, with CTG demonstrating a greater gain in keratinized mucosa width.
ADMA presents a viable alternative for treating gingival recessions, with only one minor complication reported, while CTG may be preferred if increasing keratinized mucosa width is a primary goal.
Acellular dermal matrix allograft versus autogenous connective tissue grafts for thickening soft tissue and covering multiple gingival recessions: a 5-year preference clinical study.Kroiss, S., Rathe, F., Sader, R., et al.[2021]

Citations

Acellular dermal matrix and subepithelial connective tissue grafts for root coverage: A systematic review. [2022]
Comparison of the clinical outcomes of connective tissue and acellular dermal matrix in combination with double papillary flap for root coverage: A 6-month trial. [2022]
Acellular dermal matrix allograft versus autogenous connective tissue grafts for thickening soft tissue and covering multiple gingival recessions: a 5-year preference clinical study. [2021]
Free gingival graft and acellular dermal matrix for gingival augmentation: a 15-year clinical study. [2020]
Acellular dermal matrix allografts to achieve increased attached gingiva. Part 2. A histological comparative study. [2022]
Effectiveness of acellular dermal matrix graft with a coronally advanced flap for the treatment of Miller Class I/II single gingival recession with thin gingival phenotype: study protocol for a split-mouth randomised controlled trial. [2022]
Comparison of acellular dermal matrix allograft (ADMA) and a subepithelial connective tissue graft (SCTG) for the treatment of gingival recession. [2022]
A 6-month comparative clinical study of a conventional and a new surgical approach for root coverage with acellular dermal matrix. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity